secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zai Lab Ltd (ZLAB)
CIK:        0001704292
Form:       8-K
Filed at:   2025-02-27T23:59:59+00:00
Accession:  0001628280-25-008406
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zai Lab Q4 2024 revenue $109.1M (+66% YoY); guides FY2025 revenue $560-590M
---------------------------------------------------------------------------

- Total revenues $399.0M for FY2024, up 50% YoY; product revenue $397.6M, up 49% YoY.
- VYVGART franchise net revenue $93.6M in first full year; ZEJULA $187.1M (+11% YoY); NUZYRA $43.2M (+99% YoY).
- Loss from operations decreased 23% to $282.1M for FY2024; net loss per ADS $2.60 vs $3.46 in 2023.
- Cash position $879.7M as of Dec 31, 2024; expects adjusted profitability (non-GAAP) in Q4 2025.
- ZL-1310 (DLL3 ADC) SCLC trial showed 74% ORR; NDA accepted for KarXT in schizophrenia in China.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1704292/000162828025008406/0001628280-25-008406-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1704292/000162828025008406/zlab-20250227.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-008406

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer